Filtered By:
Cancer: Breast Cancer
Drug: Xeloda
This page shows you your search results in order of date.
Order by Relevance | Date
Total 242 results found since Jan 2013.
HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer
Cancer Res Commun. 2023 Sep 11. doi: 10.1158/2767-9764.CRC-23-0302. Online ahead of print.ABSTRACTThe oncogenic receptor HER2 is overexpressed in many cancers, including up to 20% of breast cancers. Despite the availability of HER2-targeted treatments, patients' disease often progresses during therapy, underscoring the need for novel treatment strategies. The addition of tucatinib, a reversible, highly selective HER2 tyrosine kinase inhibitor (TKI), to treatment with trastuzumab and capecitabine significantly improved survival outcomes of patients with HER2-positive metastatic breast cancer, including those with active bra...
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Devra Olson Janelle Taylor Kelsi Willis Kelly Hensley Sean Allred Margo Zaval Lauren Farr Robert Thurman Nishi Jain Renee Hein Michelle Ulrich Scott Peterson Anita Kulukian Source Type: research
Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases
CONCLUSIONS: SRS in combination with tucatinib, capecitabine, and trastuzumab appears to be a safe and feasible treatment for HER2 + brain metastases. Further prospective evaluation of potential synergistic effects is warranted.PMID:37490232 | DOI:10.1007/s11060-023-04402-7
Source: Cancer Control - July 25, 2023 Category: Cancer & Oncology Authors: Vaseem M Khatri Matthew N Mills Daniel E Oliver Hsiang-Hsuan Michael Yu Michael A Vogelbaum Peter A Forsyth Hatem H Soliman Hyo S Han Kamran A Ahmed Source Type: research
Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
CONCLUSIONS: We show impaired survival irrespective of endocrine or chemotherapy-based treatments for patients with HR+/HER2- MBC harbouring plasma TP53 mutations. Early ctDNA suppression may provide treatment efficacy predictions. Further validation to fully demonstrate clinical utility of ctDNA dynamics is warranted.PMID:37490393 | DOI:10.1158/1078-0432.CCR-23-0956
Source: Clinical Cancer Research - July 25, 2023 Category: Cancer & Oncology Authors: Javier Pascual Miguel Gil-Gil Paula Proszek Christoph Zielinski Alistair Reay Manuel Ruiz-Borrego Rosalind Cutts Eva M Ciruelos Gil Andrew Feber Montserrat Mu ñoz-Mateu Claire Swift Bego ña Bermejo Jesus Herranz Mireia Margeli Vila Antonio Ant ón Zsuzs Source Type: research
Metastatic colon cancer treated using traditional Chinese medicine combined with chemotherapy: A case report
CONCLUSION: TCM may be an effective adjunct therapy in the treatment of patients with metastatic CC.PMID:37469725 | PMC:PMC10353496 | DOI:10.12998/wjcc.v11.i19.4670
Source: Clinical Breast Cancer - July 20, 2023 Category: Cancer & Oncology Authors: Chen-Geng Deng Meng-Yuan Tang Xue Pan Zhao-Heng Liu Source Type: research
Simultaneously metastatic cholangiocarcinoma and small intestine cancer from breast cancer misdiagnosed as primary cholangiocarcinoma: A case report
CONCLUSION: Simultaneous metastatic cholangiocarcinoma and small intestine cancer from breast cancer are rare and the prognosis is extremely poor. Improving preoperative diagnostic accuracy is beneficial to avoid excessive surgical treatment. Treatment should be aimed at relieving biliary obstruction and abdominal pain, and then supplemented with chemotherapy and targeted therapy to control tumor progression and prolong the patient's life.PMID:37449239 | PMC:PMC10336993 | DOI:10.12998/wjcc.v11.i18.4446
Source: Clinical Genitourinary Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Xin Jiao Mi-Mi Zhai Fang-Zhou Xing Xiao-Ling Wang Source Type: research
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial
CONCLUSION AND RELEVANCE: This randomized clinical trial found significantly prolonged TTF and PFS for oral VEX but no improvement in OS compared with intravenous paclitaxel, despite increased but still manageable toxic effects. The VEX regimen may provide more prolonged disease control than weekly paclitaxel for ER+/ERBB2- MBC.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02954055.PMID:37440239 | DOI:10.1001/jamaoncol.2023.2150
Source: Cancer Control - July 13, 2023 Category: Cancer & Oncology Authors: Elisabetta Munzone Meredith M Regan Saverio Cinieri Emilia Montagna Laura Orlando Ruichao Shi Enrico Campadelli Lorenzo Gianni Michela Palleschi Fausto Petrelli Carmelo Bengala Daniele Generali Elena Collov à Fabio Puglisi Elisabetta Cretella Claudio Zam Source Type: research
Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Breast Cancer Patients with Residual Disease following Neoadjuvant Chemotherapy: A Prospective Clinical Trial
CONCLUSIONS: Adjuvant chemoradiation with capecitabine is feasible and tolerable in patients with breast cancer. Although current studies using adjuvant capecitabine for residual disease following neoadjuvant chemotherapy have specified sequential treatment of capecitabine and radiation, these results support the conduct of randomized trials in this setting to investigate the efficacy of concurrent radiation with capecitabine and provide patient-reported toxicity estimates for trial design.PMID:37433376 | DOI:10.1016/j.ijrobp.2023.06.076
Source: Health Physics - July 11, 2023 Category: Physics Authors: Meridith L Balbach Alexander D Sherry Brent N Rexer Vandana G Abramson Kenneth J Niermann Corbin R Johnson Ben Ho Park Ingrid A Mayer A Bapsi Chakravarthy Source Type: research
